LY 288513

Known as: LY288513 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
The SAR optimization of the pyrazoline template resulted in novel 3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazol-4-yl)-indole… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 5
  • table 1
Is this relevant?
2004
2004
This study investigated the behavioral mechanisms underlying the anxiogenic, or anxiolytic mediated effects of CCK(2) receptor… (More)
Is this relevant?
1998
1998
Defensive rage behavior is mediated over a descending pathway from the medial hypothalamus to the dorsolateral midbrain… (More)
Is this relevant?
1997
1997
Cholecystokinin (CCK) is one of the most abundant neuropeptides in the brain. It is found in the highest levels in cortical and… (More)
  • table I
  • table II
Is this relevant?
1997
1997
Pre-pulse inhibition (PPI) of the acoustic startle response is the diminution of the startle response when the startle stimulus… (More)
Is this relevant?
1996
1996
In order to explore the potential clinical utility of CCK-B antagonists for the treatment of nicotine withdrawal symptoms, the… (More)
Is this relevant?
1996
1996
The potency and specificity of five proposed cholecystokinin-B receptor antagonists, YM022, RP73870, L-740,093, L-365,260 and… (More)
Is this relevant?
1993
1993
In order to explore the potential clinical utility of CCK-B antagonists for the treatment of benzodiazepine withdrawal symptoms… (More)
Is this relevant?
1993
1993
The diphenylpyrazolidinone cholecystokinin (CCK)-B antagonist LY262691 has recently been demonstrated to decrease the number of… (More)
Is this relevant?